Clinical Oncology Next Generation Sequencing Market Size, Scope And Growth 2025 To 2034

Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations

What Is the Growth Potential of the Clinical Oncology Next Generation Sequencing Market in the Next Decade?
The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

What Are the Major Drivers Influencing the Clinical Oncology Next Generation Sequencing Market?
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, there were about 18.1 million cancer survivors in the United States. This figure is projected to rise to 22.5 million by 2032. By 2040, it's expected that the number of new cancer cases each year will reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market.

Which Segment Holds the Largest Share in the Clinical Oncology Next Generation Sequencing Market?
The clinical oncology next generation sequencingmarket covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

What Are the Major Trends Impacting the Clinical Oncology Next Generation Sequencing Market?
Major companies operating in the clinical oncology next-generation sequencing market are innovating new products such as BenchMark ULTRA PLUS system to increase their profitability in the market. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it helps ensure the accuracy and efficiency of diagnostic tests, thereby contributing to improved patient care. For instance, in June 2022, Roche, a Switzerland-based pharmaceutical company, launched the BenchMark ULTRA PLUS system, its most cutting-edge platform for tissue staining. It helps clinicians to decide on a patient's course of therapy in a timely manner, the system offers speedy and accurate test results.

Which Major Companies Are Operating in the Clinical Oncology Next Generation Sequencing Market?
Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Get the full clinical oncology next generation sequencing market report here:
https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Which Region Is Expected to Lead the Clinical Oncology Next Generation Sequencing Market by 2029?
North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company